Accès ouvert

Neurodevelopment at 11 months after starting antiretroviral therapy within 3 weeks of life

Article scientifique 2019 Anglais

Résumé

BACKGROUND: Antiretroviral therapy (ART) started between 7 and 12 weeks of age improves neurodevelopmental outcomes in HIV-infected (HIV+) infants, but the impact of even earlier initiation is not yet described. OBJECTIVES: We assessed the early neurodevelopment of HIV+ infants who started ART within 21 days of life. METHOD: Participants were enrolled from the public sector birth HIV-diagnosis programme. Inclusion criteria included the following: birth weight > 2000 g, infant commencing ART < 6 weeks and no infant cytomegalovirus disease. Antiretroviral therapy included Zidovudine/Lamivudine/Nevirapine for the first 2 weeks, the latter then replaced by Lopinavir/Ritonavir. Once body weight > 3 kg and gestational age > 44 weeks, Abacavir replaced Zidovudine. The Griffiths mental development scales (GMDS) were administered at 10-12 months. RESULTS: Of 29 infants assessed, 23 (79%) were girls. Mean birth weight was 3002 ± 501 g. Twenty-four mothers (83%) received ART during pregnancy. Seven (24%) infants were diagnosed HIV+ within 48 h of birth. Median [interquartile range] viral load (VL) at diagnosis was 3904 [259-16 922] copies/mL, age starting ART was 6.0 [3-10] days and age at VL suppression was 19.1 [15-36] weeks. At the GMDS assessment, nine (31%) participants had detectable VL and 26 (90%) had World Health Organization (WHO) clinical stage I disease. The GMDS was performed at a mean age of 11.5 ± 0.8 months. Mean quotients were within the average range: Global Griffiths score was 103.6 ± 10.9 and mean quotients on the subscales ranged from lowest 95.9 ± 13.4 for locomotor to highest 112.8 ± 11.3 for hearing-and-language. CONCLUSION: Preliminary findings in this small group suggest that early neurodevelopmental scores are within the normal range in infants with perinatal HIV infection who started ART at a median of 6 days.

Citer ce document

Laughton, B., Naidoo, S., Dobbels, E., Boivin, M., Rensburg, A., Glashoff, R., Zyl, G., Kruger, M., Cotton, M. (2019). Neurodevelopment at 11 months after starting antiretroviral therapy within 3 weeks of life. https://doi.org/10.4102/sajhivmed.v20i1.1008

Accès au document

Voir sur le dépôt source

Ce document est hébergé sur son dépôt institutionnel d'origine.

Auteur(s)

Barbara Laughton Shalena Naidoo Els Dobbels Michael J. Boivin Anita Janse van Rensburg Richard H. Glashoff Gert U. van Zyl Mariana Kruger Mark F. Cotton

Statistiques

Consultations : 1

Téléchargements : 0